? Core A The overall goals of the Mayo Clinic SPORE in Ovarian Cancer are to stimulate innovative research in ovarian cancer and to expedite the translation of discoveries into new and better methods of prevention, detection and treatment of this disease. The Administrative Core has facilitated progress toward these goals by serving as the organizational hub of the Mayo Ovarian SPORE during Years 1-5 of funding. During the next funding period (Years 6-10), it will continue to provide organizational and communications support for the SPORE leadership, research projects, scientific cores and developmental programs [Developmental Research Program (DRP) and Career Development Program (CDP)]. Specifically, the Administrative Core will: 1) provide leadership and organizational support to SPORE investigators; 2) oversee formal procedures for scientific review of SPORE research projects; 3) oversee and facilitate the efforts of all cores; 4) manage and coordinate SPORE fiscal activities; 5) monitor accrual, including minority accrual, to all SPORE clinical trials, population research studies and biospecimen collections; 6) provide guidance and administrative support to the DRP and CDP leadership; 7) facilitate the activities of the Executive Committee and implement its decisions; 8) facilitate engagement of the SPORE advocates; 9) facilitate reviews of the SPORE by the EAB and ISAC; 10) organize monthly SPORE seminars, scientific meetings and the annual retreat; 11) assure ongoing integration of the Ovarian SPORE with the Mayo Clinic Cancer Center and its Women's Cancer Program; 12) serve as the administrative liaison between the Mayo Ovarian SPORE, the NCI SPORE Program, other Mayo SPOREs, and external collaborators; 13) identify and catalyze research collaborations in ovarian cancer, including collaborations with the other Ovarian SPOREs; 14) communicate SPORE-related research developments and opportunities to Mayo investigators; and 15) assist the SPORE Director in preparing reports of Ovarian SPORE activities, including annual progress reports and the competitive renewal application.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA136393-07
Application #
9149468
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Kuzmin, Igor A
Project Start
Project End
Budget Start
2016-09-01
Budget End
2017-08-31
Support Year
7
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Wahner Hendrickson, Andrea E; Menefee, Michael E; Hartmann, Lynn C et al. (2018) A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors. Clin Cancer Res 24:744-752
Natanzon, Yanina; Goode, Ellen L; Cunningham, Julie M (2018) Epigenetics in ovarian cancer. Semin Cancer Biol 51:160-169
Knijnenburg, Theo A; Wang, Linghua; Zimmermann, Michael T et al. (2018) Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. Cell Rep 23:239-254.e6
Jung, DeokBeom; Khurana, Ashwani; Roy, Debarshi et al. (2018) Quinacrine upregulates p21/p27 independent of p53 through autophagy-mediated downregulation of p62-Skp2 axis in ovarian cancer. Sci Rep 8:2487
Liu, Gang; Mukherjee, Bhramar; Lee, Seunggeun et al. (2018) Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. Am J Epidemiol 187:366-377
Ong, Jue-Sheng; Hwang, Liang-Dar; Cuellar-Partida, Gabriel et al. (2018) Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol 47:450-459
Kalli, Kimberly R; Block, Matthew S; Kasi, Pashtoon M et al. (2018) Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clin Cancer Res 24:3014-3025
Zhang, Qing; Wang, Chen; Cliby, William A (2018) Cancer-associated stroma significantly contributes to the mesenchymal subtype signature of serous ovarian cancer. Gynecol Oncol :
Morehead, Lauren C; Cannon, Martin J (2018) Further clinical advancement of dendritic cell vaccination against ovarian cancer. Ann Res Hosp 2:
Botuyan, Maria Victoria; Cui, Gaofeng; Drané, Pascal et al. (2018) Mechanism of 53BP1 activity regulation by RNA-binding TIRR and a designer protein. Nat Struct Mol Biol 25:591-600

Showing the most recent 10 out of 294 publications